In addition, in May 2025, the administration published an executive order regarding most favored nation (“MFN”) drug pricing, which is sometimes referred to as international reference pricing. This executive order directs HHS to communicate MFN price targets to pharmaceutical manufacturers, and if significant progress towards MFN pricing is not delivered, to propose a rule making plan to implement MFN pricing.
All entries for: Quoin Pharmaceuticals, Ltd.
March 26, 2026
Quoin Pharmaceuticals, Ltd.
Neutral Outlook
Ashburn, VA
1-50 employees
The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These provisions have been and may continue to be subject to legal challenges. It is unclear what policies will be advanced with respect to IRA implementation and other drug pricing proposals.
Disease Area: Dermatology, Rare Diseases
Drug Type: Biologic, Small Molecule